Oxaliplatin and fixed-rate infusional gemcitabine in the second-line treatment of patients with metastatic colon cancer: Final results of a phase II trial prematurely closed as a result of poor accrual

Gilberto Lopes, Jose Quesada, Eugene Ahn, Aurea Flores, Afonso Ribeiro, Caio Max Rocha-Lima

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Second-line therapy of advanced colorectal cancer (CRC) after failure of a combination of irinotecan, a fluoropyrimidine, and bevacizumab includes the use of oxaliplatin and a fluoropyrimidine. In animal models, synergistic effects of gemcitabine and platinum agents have been established. Additionally, superior antitumor activity of prolonged administration of gemcitabine compared with bolus administration has been demonstrated in vivo against murine colon tumors. Patients and Methods: A 2-stage phase II trial was developed to assess the efficacy (primary endpoint response rate) and safety of gemcitabine 1000 mg/m2 over 100 minutes on days 1 and 15 in combination with oxaliplatin 100 mg/m2 over 2 hours on days 2 and 16, every 4 weeks. Patients with metastatic CRC in whom irinotecan and a fluoropyrimidine treatment had failed were enrolled. Calcium and magnesium infusion was routinely given before and after oxaliplatin administration. Results: Because of slow accrual as a result of oxaliplatin becoming more commonly used in first-line treatment, the trial was stopped with only 10 patients enrolled. Eight were men and 2 were women. Median age was 58.5 years (range, 47-72 years). Nine patients had an Eastern Cooperative Oncology Group performance status of 0/1. A median of 3.5 cycles was administered (range, 1-9; total, 42). Six patients had stable disease and 1 had progressive disease. Two patients had confirmed partial responses, and 1 patient had a partial response but developed necrotizing fasciitis, declined surgical treatment, and died before a confirmatory scan could be perfomed. The regimen was otherwise well tolerated: I patient developed grade 3 neutropenia. With a median follow-up of 5.5 months, 4 patients have died. The time to treatment failure was 3.7 months. Conclusion: Despite premature study closure because of poor accrual, oxaliplatin in combination with fixed-rate infusional gemcitabine seems to be a safe and potentially effective regimen in the treatment of CRC. Further studies should be considered with the addition of targeted therapy.

Original languageEnglish
Pages (from-to)641-645
Number of pages5
JournalClinical Colorectal Cancer
Volume6
Issue number9
DOIs
StatePublished - Jan 1 2007

Fingerprint

oxaliplatin
gemcitabine
Colonic Neoplasms
irinotecan
Colorectal Neoplasms
Therapeutics
Necrotizing Fasciitis

Keywords

  • Chemotherapy
  • Fluoropyrimidines
  • Irinotecan
  • Leucovorin
  • Performance status

ASJC Scopus subject areas

  • Oncology

Cite this

Oxaliplatin and fixed-rate infusional gemcitabine in the second-line treatment of patients with metastatic colon cancer : Final results of a phase II trial prematurely closed as a result of poor accrual. / Lopes, Gilberto; Quesada, Jose; Ahn, Eugene; Flores, Aurea; Ribeiro, Afonso; Rocha-Lima, Caio Max.

In: Clinical Colorectal Cancer, Vol. 6, No. 9, 01.01.2007, p. 641-645.

Research output: Contribution to journalArticle

@article{067a1ea32c6e432388f256b0ab4318ee,
title = "Oxaliplatin and fixed-rate infusional gemcitabine in the second-line treatment of patients with metastatic colon cancer: Final results of a phase II trial prematurely closed as a result of poor accrual",
abstract = "Background: Second-line therapy of advanced colorectal cancer (CRC) after failure of a combination of irinotecan, a fluoropyrimidine, and bevacizumab includes the use of oxaliplatin and a fluoropyrimidine. In animal models, synergistic effects of gemcitabine and platinum agents have been established. Additionally, superior antitumor activity of prolonged administration of gemcitabine compared with bolus administration has been demonstrated in vivo against murine colon tumors. Patients and Methods: A 2-stage phase II trial was developed to assess the efficacy (primary endpoint response rate) and safety of gemcitabine 1000 mg/m2 over 100 minutes on days 1 and 15 in combination with oxaliplatin 100 mg/m2 over 2 hours on days 2 and 16, every 4 weeks. Patients with metastatic CRC in whom irinotecan and a fluoropyrimidine treatment had failed were enrolled. Calcium and magnesium infusion was routinely given before and after oxaliplatin administration. Results: Because of slow accrual as a result of oxaliplatin becoming more commonly used in first-line treatment, the trial was stopped with only 10 patients enrolled. Eight were men and 2 were women. Median age was 58.5 years (range, 47-72 years). Nine patients had an Eastern Cooperative Oncology Group performance status of 0/1. A median of 3.5 cycles was administered (range, 1-9; total, 42). Six patients had stable disease and 1 had progressive disease. Two patients had confirmed partial responses, and 1 patient had a partial response but developed necrotizing fasciitis, declined surgical treatment, and died before a confirmatory scan could be perfomed. The regimen was otherwise well tolerated: I patient developed grade 3 neutropenia. With a median follow-up of 5.5 months, 4 patients have died. The time to treatment failure was 3.7 months. Conclusion: Despite premature study closure because of poor accrual, oxaliplatin in combination with fixed-rate infusional gemcitabine seems to be a safe and potentially effective regimen in the treatment of CRC. Further studies should be considered with the addition of targeted therapy.",
keywords = "Chemotherapy, Fluoropyrimidines, Irinotecan, Leucovorin, Performance status",
author = "Gilberto Lopes and Jose Quesada and Eugene Ahn and Aurea Flores and Afonso Ribeiro and Rocha-Lima, {Caio Max}",
year = "2007",
month = "1",
day = "1",
doi = "10.3816/CCC.2007.n.032",
language = "English",
volume = "6",
pages = "641--645",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier",
number = "9",

}

TY - JOUR

T1 - Oxaliplatin and fixed-rate infusional gemcitabine in the second-line treatment of patients with metastatic colon cancer

T2 - Final results of a phase II trial prematurely closed as a result of poor accrual

AU - Lopes, Gilberto

AU - Quesada, Jose

AU - Ahn, Eugene

AU - Flores, Aurea

AU - Ribeiro, Afonso

AU - Rocha-Lima, Caio Max

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Background: Second-line therapy of advanced colorectal cancer (CRC) after failure of a combination of irinotecan, a fluoropyrimidine, and bevacizumab includes the use of oxaliplatin and a fluoropyrimidine. In animal models, synergistic effects of gemcitabine and platinum agents have been established. Additionally, superior antitumor activity of prolonged administration of gemcitabine compared with bolus administration has been demonstrated in vivo against murine colon tumors. Patients and Methods: A 2-stage phase II trial was developed to assess the efficacy (primary endpoint response rate) and safety of gemcitabine 1000 mg/m2 over 100 minutes on days 1 and 15 in combination with oxaliplatin 100 mg/m2 over 2 hours on days 2 and 16, every 4 weeks. Patients with metastatic CRC in whom irinotecan and a fluoropyrimidine treatment had failed were enrolled. Calcium and magnesium infusion was routinely given before and after oxaliplatin administration. Results: Because of slow accrual as a result of oxaliplatin becoming more commonly used in first-line treatment, the trial was stopped with only 10 patients enrolled. Eight were men and 2 were women. Median age was 58.5 years (range, 47-72 years). Nine patients had an Eastern Cooperative Oncology Group performance status of 0/1. A median of 3.5 cycles was administered (range, 1-9; total, 42). Six patients had stable disease and 1 had progressive disease. Two patients had confirmed partial responses, and 1 patient had a partial response but developed necrotizing fasciitis, declined surgical treatment, and died before a confirmatory scan could be perfomed. The regimen was otherwise well tolerated: I patient developed grade 3 neutropenia. With a median follow-up of 5.5 months, 4 patients have died. The time to treatment failure was 3.7 months. Conclusion: Despite premature study closure because of poor accrual, oxaliplatin in combination with fixed-rate infusional gemcitabine seems to be a safe and potentially effective regimen in the treatment of CRC. Further studies should be considered with the addition of targeted therapy.

AB - Background: Second-line therapy of advanced colorectal cancer (CRC) after failure of a combination of irinotecan, a fluoropyrimidine, and bevacizumab includes the use of oxaliplatin and a fluoropyrimidine. In animal models, synergistic effects of gemcitabine and platinum agents have been established. Additionally, superior antitumor activity of prolonged administration of gemcitabine compared with bolus administration has been demonstrated in vivo against murine colon tumors. Patients and Methods: A 2-stage phase II trial was developed to assess the efficacy (primary endpoint response rate) and safety of gemcitabine 1000 mg/m2 over 100 minutes on days 1 and 15 in combination with oxaliplatin 100 mg/m2 over 2 hours on days 2 and 16, every 4 weeks. Patients with metastatic CRC in whom irinotecan and a fluoropyrimidine treatment had failed were enrolled. Calcium and magnesium infusion was routinely given before and after oxaliplatin administration. Results: Because of slow accrual as a result of oxaliplatin becoming more commonly used in first-line treatment, the trial was stopped with only 10 patients enrolled. Eight were men and 2 were women. Median age was 58.5 years (range, 47-72 years). Nine patients had an Eastern Cooperative Oncology Group performance status of 0/1. A median of 3.5 cycles was administered (range, 1-9; total, 42). Six patients had stable disease and 1 had progressive disease. Two patients had confirmed partial responses, and 1 patient had a partial response but developed necrotizing fasciitis, declined surgical treatment, and died before a confirmatory scan could be perfomed. The regimen was otherwise well tolerated: I patient developed grade 3 neutropenia. With a median follow-up of 5.5 months, 4 patients have died. The time to treatment failure was 3.7 months. Conclusion: Despite premature study closure because of poor accrual, oxaliplatin in combination with fixed-rate infusional gemcitabine seems to be a safe and potentially effective regimen in the treatment of CRC. Further studies should be considered with the addition of targeted therapy.

KW - Chemotherapy

KW - Fluoropyrimidines

KW - Irinotecan

KW - Leucovorin

KW - Performance status

UR - http://www.scopus.com/inward/record.url?scp=35348870002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348870002&partnerID=8YFLogxK

U2 - 10.3816/CCC.2007.n.032

DO - 10.3816/CCC.2007.n.032

M3 - Article

C2 - 17945036

AN - SCOPUS:35348870002

VL - 6

SP - 641

EP - 645

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 9

ER -